Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...

To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". Sarepta Therapeutics has an accrual ratio of 0.79 for the year to September 2024.

Analyst Luke Sergott of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $209.00.Don't ...

Dyne Therapeutics Inc.-0.13% $3.03B ...

Mutual of America Capital Management LLC cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) ...

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...